Axon Enterprise (AXON) Expected to Announce Earnings on Tuesday

Axon Enterprise (NASDAQ:AXON) will likely be announcing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Axon Enterprise to post earnings of $1.65 per share and revenue of $755.2910 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Axon Enterprise Price Performance

Shares of AXON opened at $429.67 on Tuesday. The company has a market capitalization of $33.91 billion, a price-to-earnings ratio of 135.97, a P/E/G ratio of 12.94 and a beta of 1.48. Axon Enterprise has a fifty-two week low of $396.41 and a fifty-two week high of $885.91. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. The business’s 50-day moving average is $555.10 and its 200-day moving average is $645.15.

Insider Activity at Axon Enterprise

In related news, CFO Brittany Bagley sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the sale, the chief financial officer directly owned 103,501 shares in the company, valued at approximately $60,030,580. The trade was a 1.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $552.60, for a total value of $11,052,000.00. Following the sale, the president directly owned 249,502 shares of the company’s stock, valued at $137,874,805.20. The trade was a 7.42% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 48,040 shares of company stock valued at $27,249,338. Insiders own 5.70% of the company’s stock.

Institutional Trading of Axon Enterprise

A number of institutional investors and hedge funds have recently modified their holdings of the company. Brighton Jones LLC bought a new position in Axon Enterprise in the 4th quarter worth $480,000. NewEdge Advisors LLC grew its position in shares of Axon Enterprise by 41.1% in the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after purchasing an additional 668 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Axon Enterprise by 8.4% in the first quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after purchasing an additional 157 shares during the period. Woodline Partners LP lifted its position in shares of Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after purchasing an additional 2,003 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Axon Enterprise during the 2nd quarter valued at approximately $284,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on AXON. Northcoast Research upgraded shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective on the stock in a research note on Tuesday, January 6th. Morgan Stanley lowered their price target on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Wall Street Zen downgraded shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Barclays reduced their price objective on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Finally, The Goldman Sachs Group dropped their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Fifteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $805.71.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.